宜明昂科-B(01541)_个股概要_股票价格_最新资讯_行情走势_历史数据 - 老虎社区

应交易所要求，美/港股行情延时15分钟展示，下载APP即可免费查看实时行情。

关闭

01541 宜明昂科-B

未开盘 07-21 16:08:04

3.370

-0.060

-1.75%

最高3.480	最低3.370	成交量11.80万
今开3.480	昨收3.430	日振幅3.21%
总市值14.49亿	流通市值14.12亿	总股本4.30亿
成交额40.53万	换手率0.03%	流通股本4.19亿
市净率--	ROE--	每股收益0.00
52周最高--	52周最低--	市盈率--
股息--	股息收益率--	ROA--

数据加载中...

北京优虎网络科技有限公司

免责声明:香港交易所资讯服务有限公司、其控股公司及／或该等控股公司的任何附属公司均竭力确保所提供信息的准确和可靠度，但不能保证其绝对准确和可靠，且亦不会承担因任何不准确或遗漏而引起的任何损失或损害的责任（不管是否侵权法下的责任或合约责任又或其它责任）

{"stockData":{"symbol":"01541","market":"HK","secType":"STK","nameCN":"宜明昂科-B","latestPrice":3.37,"timestamp":1784621284258,"preClose":3.43,"halted":0,"volume":118000,"delay":0,"changeRate":-0.017492711370262405,"floatShares":419000000,"shares":430000000,"eps":-0.53,"marketStatus":"未开盘","change":-0.06,"latestTime":"07-21 16:08:04","open":3.48,"high":3.48,"low":3.37,"amount":405340,"amplitude":0.03207,"askPrice":3.41,"askSize":200,"bidPrice":3.37,"bidSize":600,"shortable":0,"etf":0,"ttmEps":-0.589757,"tradingStatus":0,"nextMarketStatus":{"tag":"开盘","tradingStatus":2,"beginTime":1784683800000},"marketStatusCode":0,"adr":0,"listingDate":1693843200000,"exchange":"SEHK","adjPreClose":3.43,"openAndCloseTimeList":[[1784597400000,1784606400000],[1784610000000,1784620800000]],"volumeRatio":0.18399550929944397,"lotSize":200,"spreadScale":0,"tradeCurrency":"HKD"},"requestUrl":"/m/hq/s/01541","defaultTab":"news","newsList":[{"id":"1140553009","title":"宜明昂科-B 7月17日回购6.38万股股份，耗资约22.04万港元","url":"https://stock-news.laohu8.com/highlight/detail?id=1140553009","media":"公告速递","labels":["shareholding","SGX"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/1140553009?lang=zh_cn&edition=full","pubTime":"2026-07-17 19:16","pubTimestamp":1784287017,"startTime":"0","endTime":"0","summary":"宜明昂科生物医药技术（上海）股份有限公司于2026年7月17日公告，显示公司当日于香港联交所场内回购H股6.38万股，占当日现有已发行股份约0.0152%。本次回购每股价格介乎港币3.39港元至3.59港元，回购总金额约22.04万港元。截至目前，公司已依据该授权累计在香港联交所或其他证券交易所回购1,850,400股，占授权生效当日已发行股份总数约0.429%。公司确认，本次回购已根据香港联交所证券上市规则及相关法律规定进行。","market":"sh","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":"宜明昂科-B 7月17日回购6.38万股股份，耗资约22.04万港元","news_tag":"shareholding,SGX","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["01541"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2652843400","title":"宜明昂科-B(01541)7月17日斥资22.04万港元回购6.38万股","url":"https://stock-news.laohu8.com/highlight/detail?id=2652843400","media":"智通财经","labels":["shareholding"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2652843400?lang=zh_cn&edition=full","pubTime":"2026-07-17 19:14","pubTimestamp":1784286898,"startTime":"0","endTime":"0","summary":"智通财经APP讯，宜明昂科-B(01541)发布公告，于2026年7月17日斥资22.04万港元回购6.38万股。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://www.zhitongcaijing.com/content/detail/1469171.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"shareholding","news_rank":0,"length":0,"strategy_id":0,"source":"stock_zhitongcaijing","symbols":["01541","BK1161"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2651195643","title":"【券商聚焦】国元国际予宜明昂科-B(01541)买入评级 指核心产品临床数据优秀","url":"https://stock-news.laohu8.com/highlight/detail?id=2651195643","media":"金吾财讯","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2651195643?lang=zh_cn&edition=full","pubTime":"2026-07-13 14:08","pubTimestamp":1783922892,"startTime":"0","endTime":"0","summary":"金吾财讯 | 国元证券经纪 发布研报指，宜明昂科-B核心产品IMM0306在2026年欧洲抗风湿病联盟年会上公布的治疗系统性红斑狼疮的Ib期临床数据优秀，研究达到主要终点。报告强调，公司是CD47靶点开发的全球创新引领者，其CD47融合蛋白IMM01已完成超过300例患者的临床试验，安全性与疗效良好。CD47CD20双抗临床数据优秀，有望成为自免领域重磅药物，CD47三期顺利推进中。","market":"nz","thumbnail":"https://static.szfiu.com/news/20250109/NjdhYmE3ZDczMTc4NjgyMDYzMDA3NjI=.jpg","type":0,"news_type":0,"thumbnails":["https://static.szfiu.com/news/20250109/NjdhYmE3ZDczMTc4NjgyMDYzMDA3NjI=.jpg"],"rights":null,"property":["rate"],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"1985706","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["KCE","01541"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2651328160","title":"国元国际：首予宜明昂科-B(01541)“买入”评级 目标价6.28港元","url":"https://stock-news.laohu8.com/highlight/detail?id=2651328160","media":"智通财经","labels":["shareholding"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2651328160?lang=zh_cn&edition=full","pubTime":"2026-07-13 10:46","pubTimestamp":1783910796,"startTime":"0","endTime":"0","summary":"预计宜明昂科-B2026至2028年实现收入0.32/2.62/4.82亿元人民币。根据DCF模型计算，得出目标市值是27.11亿港元，目标价6.28港元，给予“买入”评级，较现价有83%的升幅。即便考虑开放标签设计对应答率的放大效应，IMM0306的绝对疗效水平仍位于SLE在研管线前列。无严重感染事件与IgG维持正常一致，为长期用药提供了安全窗口。目前公司的CD47融合蛋白总共做了超过300例患者的临床试验，疗效及安全性良好。","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":["rate"],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://www.zhitongcaijing.com/content/detail/1466414.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"shareholding","news_rank":0,"length":0,"strategy_id":0,"source":"stock_zhitongcaijing","symbols":["01541","EWH"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2650901520","title":"宜明昂科-B(01541.HK)：IMM0306治疗IgG4相关疾病的II/III期临床试验完成首例患者给药","url":"https://stock-news.laohu8.com/highlight/detail?id=2650901520","media":"智通财经","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2650901520?lang=zh_cn&edition=full","pubTime":"2026-07-10 12:34","pubTimestamp":1783658046,"startTime":"0","endTime":"0","summary":null,"market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.zhitongcaijing.com/immediately.html?type=ganggu","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"live_zhitongcaijing","symbols":["BK1161","01541"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2650015739","title":"宜明昂科-B(01541)：IMM0306治疗IgG4相关疾病的II/III期临床试验完成首例患者给药","url":"https://stock-news.laohu8.com/highlight/detail?id=2650015739","media":"智通财经","labels":["productRelease"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2650015739?lang=zh_cn&edition=full","pubTime":"2026-07-10 12:34","pubTimestamp":1783658046,"startTime":"0","endTime":"0","summary":"智通财经APP讯，宜明昂科-B 发布公告，IMM0306 治 疗IgG4 相关疾病 的II/III期试验顺利完成首例患者给药。在严重情况下，该疾病可能导致器官衰竭。现有免疫抑制治疗仍受限于低反应率及高复发率。研究显示，B细胞异常活化及IgG4阳性浆细胞浸润是IgG4-RD的核心病理机制，这与IMM0306的作用机制高度匹配。II/III期临床试验旨在评估IMM0306在降低IgG4-RD患者疾病复发风险方面的疗效，并以此作为其主要终点。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://www.zhitongcaijing.com/content/detail/1465754.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"productRelease","news_rank":0,"length":0,"strategy_id":0,"source":"stock_zhitongcaijing","symbols":["III","IBBQ","01541","BK4134","BK1161","BMED"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1197755592","title":"宜明昂科-B：7月9日回购63,600股，耗资约22.16万港元","url":"https://stock-news.laohu8.com/highlight/detail?id=1197755592","media":"公告速递","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/1197755592?lang=zh_cn&edition=full","pubTime":"2026-07-09 18:51","pubTimestamp":1783594274,"startTime":"0","endTime":"0","summary":"宜明昂科生物医药技术（上海）股份有限公司于2026年7月9日发布翌日披露报表，公告显示公司当日于香港联交所场内回购H股63,600股，占回购前已发行股本约0.0152%。每股价格介乎3.43港元至3.53港元，合计付出221,570港元。公司于2026年5月28日获股东大会批准可回购股份总数为43,150,769股，迄今为止已于香港联交所及其他交易所累计回购1,786,600股，占授权通过当日已发行股本总数约0.414%。","market":"sh","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":"宜明昂科-B：7月9日回购63,600股，耗资约22.16万港元","news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["01541"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2649995058","title":"宜明昂科-B(01541.HK)7月8日斥资20.14万港元回购5.56万股","url":"https://stock-news.laohu8.com/highlight/detail?id=2649995058","media":"智通财经","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2649995058?lang=zh_cn&edition=full","pubTime":"2026-07-08 20:37","pubTimestamp":1783514248,"startTime":"0","endTime":"0","summary":null,"market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.zhitongcaijing.com/immediately.html?type=ganggu","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"live_zhitongcaijing","symbols":["01541","BK1161"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2649995053","title":"宜明昂科-B(01541)7月8日斥资20.14万港元回购5.56万股","url":"https://stock-news.laohu8.com/highlight/detail?id=2649995053","media":"智通财经","labels":["shareholding"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2649995053?lang=zh_cn&edition=full","pubTime":"2026-07-08 20:37","pubTimestamp":1783514248,"startTime":"0","endTime":"0","summary":"智通财经APP讯，宜明昂科-B(01541)发布公告，于2026年7月8日斥资20.14万港元回购5.56万股。","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://www.zhitongcaijing.com/content/detail/1464919.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"shareholding","news_rank":0,"length":0,"strategy_id":0,"source":"stock_zhitongcaijing","symbols":["01541","BK1161"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1146874591","title":"宜明昂科-B回购5.56万股股份，耗资约20.14万港元","url":"https://stock-news.laohu8.com/highlight/detail?id=1146874591","media":"公告速递","labels":["shareholding","SGX"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/1146874591?lang=zh_cn&edition=full","pubTime":"2026-07-08 20:36","pubTimestamp":1783514179,"startTime":"0","endTime":"0","summary":"宜明昂科生物医药技术（上海）股份有限公司于2026年7月8日公告，开展股份购回，回购数量为55,600股，占当时已发行股本的约0.0133%。回购价格区间介乎每股3.58港元至3.67港元，合计耗资约20.14万港元。本次购回完成后，公司已发行股本为418,754,305股，库藏股数量增至1,723,000股。公司于2026年5月28日获得购回授权，总授权购回数量为43,150,769股，截至目前累计已回购1,723,000股，占授权通过当日已发行股本的约0.399%。","market":"hk","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":"宜明昂科-B回购5.56万股股份，耗资约20.14万港元","news_tag":"shareholding,SGX","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["01541"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1179417479","title":"宜明昂科-B 7月7日回购9.18万股股份，总额约33.79万港元","url":"https://stock-news.laohu8.com/highlight/detail?id=1179417479","media":"公告速递","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/1179417479?lang=zh_cn&edition=full","pubTime":"2026-07-07 19:38","pubTimestamp":1783424337,"startTime":"0","endTime":"0","summary":"宜明昂科生物医药技术（上海）股份有限公司于2026年7月7日发布公告，披露公司在香港联交所场内回购共计91,800股H股，占本次回购前公司已发行股本0.0219%。本次回购价格区间为每股3.57港元至3.86港元，合计支付金额337,936港元。公告显示，回购完成后公司已发行股本数为418,809,905股，库存股数量增至1,667,400股。公司确认本次股份购回已严格遵守香港联交所上市规则及相关法例的要求。","market":"hk","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":"宜明昂科-B 7月7日回购9.18万股股份，总额约33.79万港元","news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["01541"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1103293835","title":"宜明昂科-B回购10.84万股，耗资约40.90万港元","url":"https://stock-news.laohu8.com/highlight/detail?id=1103293835","media":"公告速递","labels":["shareholding","SGX"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/1103293835?lang=zh_cn&edition=full","pubTime":"2026-07-06 21:06","pubTimestamp":1783343198,"startTime":"0","endTime":"0","summary":"宜明昂科生物医药技术（上海）股份有限公司于2026年7月6日发布翌日报表公告，披露公司于当日回购普通股H股共计10.84万股，占前一次披露时已发行股本约0.0259%。本次回购价格区间为每股3.73港元至3.85港元，合计涉资409,034港元，折合约40.90万港元。该回购基于公司于2026年5月28日通过的购回授权，授权可回购股份总数为43,150,769股，截至目前已于交易所回购1,575,600股，占授权通过时公司已发行股本的约0.365%。","market":"hk","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":"宜明昂科-B回购10.84万股，耗资约40.90万港元","news_tag":"shareholding,SGX","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["01541"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2649596624","title":"宜明昂科-B(01541)7月6日斥资40.9万港元回购10.84万股","url":"https://stock-news.laohu8.com/highlight/detail?id=2649596624","media":"智通财经","labels":["shareholding"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2649596624?lang=zh_cn&edition=full","pubTime":"2026-07-06 21:02","pubTimestamp":1783342956,"startTime":"0","endTime":"0","summary":"智通财经APP讯，宜明昂科-B(01541)发布公告，于2026年7月6日斥资40.9万港元回购10.84万股。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://www.zhitongcaijing.com/content/detail/1463767.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"shareholding","news_rank":0,"length":0,"strategy_id":0,"source":"stock_zhitongcaijing","symbols":["BK1161","01541"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1155233452","title":"宜明昂科-B 7月3日回购2.54万股，涉资约9.82万港元","url":"https://stock-news.laohu8.com/highlight/detail?id=1155233452","media":"公告速递","labels":["SGX"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/1155233452?lang=zh_cn&edition=full","pubTime":"2026-07-06 20:42","pubTimestamp":1783341753,"startTime":"0","endTime":"0","summary":"宜明昂科生物医药技术（上海）股份有限公司于2026年7月3日发布翌日报表，披露当日于香港联交所场内回购2.54万股H股，占回购前已发行股本约0.0061%。本次回购价格介乎每股港币3.80元至3.93元，总计约港币9.82万元。本次回购后，自2026年7月3日至2026年8月3日期间，公司将暂缓进行任何新股发行或出售、转让库存股事宜，遵守相关规则要求。公司确认，本次股份回购已经董事会正式授权，符合香港联交所证券上市规则及相关法律法规的规定。","market":"hk","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":"宜明昂科-B 7月3日回购2.54万股，涉资约9.82万港元","news_tag":"SGX","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["01541"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1118109573","title":"宜明昂科-B回购25,400股股份，耗资约9.82万港元","url":"https://stock-news.laohu8.com/highlight/detail?id=1118109573","media":"公告速递","labels":["shareholding","SGX"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/1118109573?lang=zh_cn&edition=full","pubTime":"2026-07-03 18:08","pubTimestamp":1783073287,"startTime":"0","endTime":"0","summary":"宜明昂科生物医药技术（上海）股份有限公司（股票名称：宜明昂科-B，股票代码：01541）于2026年7月3日公告回购25,400股股份，占当日公司已发行股本约0.0061%。每股回购价格介乎3.80港元至3.93港元，合计支付约9.82万港元。\n本次回购完成后，公司已发行股本变动为419,010,105股，库存股份增至1,467,200股。公司于2026年5月28日通过购回授权，可购回股份总数为43,150,769股，目前已回购1,467,200股。\n公司确认已遵守香港联合交易所有限公司证券上市规则及相关法律规定。公告由执行董事、联席公司秘书关梅签署。","market":"sh","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":"宜明昂科-B回购25,400股股份，耗资约9.82万港元","news_tag":"shareholding,SGX","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["01541"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2648500976","title":"宜明昂科-B(01541.HK)7月3日耗资约9.82万港元回购2.54万股","url":"https://stock-news.laohu8.com/highlight/detail?id=2648500976","media":"智通财经","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2648500976?lang=zh_cn&edition=full","pubTime":"2026-07-03 18:00","pubTimestamp":1783072850,"startTime":"0","endTime":"0","summary":null,"market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.zhitongcaijing.com/immediately.html?type=ganggu","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"live_zhitongcaijing","symbols":["BK1161","01541"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1113777668","title":"宜明昂科-B 6月股份变动月报：回购1,441,800股H股，总股本保持不变","url":"https://stock-news.laohu8.com/highlight/detail?id=1113777668","media":"公告速递","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/1113777668?lang=zh_cn&edition=full","pubTime":"2026-07-03 17:21","pubTimestamp":1783070477,"startTime":"0","endTime":"0","summary":"宜明昂科生物医药技术（上海）股份有限公司于2026年7月3日发布2026年6月股份变动月报表，披露截至2026年6月30日的股本情况。其中，H股数量在本月出现购回并转为库存股份的变动：报告期初H股总数为420,477,305股，本月内通过多次购回累计回购H股1,441,800股，价格区间约为每股3.1099港元至3.7611港元。回购后，419,035,505股H股为已发行股份，1,441,800股H股被列为库存股份，H股合计总数420,477,305股保持不变。非上市股份在本月无变化，仍为11,030,390股。","market":"sh","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["01541"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1136698469","title":"宜明昂科-B：交易所认定公司贷款未遵循正常商业条款","url":"https://stock-news.laohu8.com/highlight/detail?id=1136698469","media":"美股速递","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/1136698469?lang=zh_cn&edition=full","pubTime":"2026-07-02 22:01","pubTimestamp":1783000875,"startTime":"0","endTime":"0","summary":"上海证券交易所发布监管函，指出宜明昂科生物医药（上海）股份有限公司的一笔贷款安排，并未遵循正常的商业条款。这一认定引发了市场对公司内部治理和关联交易合规性的关注。","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["01541","BK1161"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1170852165","title":"宜明昂科-B：作为补救措施，将在下一年度报告中披露不合规及贷款详情等事项","url":"https://stock-news.laohu8.com/highlight/detail?id=1170852165","media":"美股速递","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/1170852165?lang=zh_cn&edition=full","pubTime":"2026-07-02 22:00","pubTimestamp":1783000818,"startTime":"0","endTime":"0","summary":"宜明昂科-B宣布，作为一项补救措施，公司计划在下一份年度报告中披露相关不合规事项的细节以及具体的贷款信息。","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["01541","BK1161"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2648579639","title":"依托高效平台技术，宜明昂科-B(01541)推动IMM2510剂型升级，提高癌症患者治疗的便捷性、依从性","url":"https://stock-news.laohu8.com/highlight/detail?id=2648579639","media":"智通财经","labels":["productRelease"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2648579639?lang=zh_cn&edition=full","pubTime":"2026-07-02 12:50","pubTimestamp":1782967835,"startTime":"0","endTime":"0","summary":"而在今年ASCO年会上，宜明昂科IMM2510凭借出众的后线鳞癌数据，有望成为填补IO耐药肺鳞癌的临床空白的关键药物。而推动IMM2510给药模式从“静脉输注主导”向“静脉+皮下”多元化选择升级，有望大幅提升患者用药依从性，推动后线肺鳞癌治疗向基层下沉，进一步提升市场可及性。","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://www.zhitongcaijing.com/content/detail/1462203.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"productRelease","news_rank":0,"length":0,"strategy_id":0,"source":"stock_zhitongcaijing","symbols":["01541","BK1161"],"isVideo":false,"video":null,"gpt_icon":0}],"profile":{"websiteUrl":"http://immuneonco.com","stockEarnings":[{"period":"1week","weight":-0.0088},{"period":"1month","weight":-0.0665},{"period":"3month","weight":-0.4077},{"period":"6month","weight":-0.3122},{"period":"1year","weight":-0.6969},{"period":"ytd","weight":-0.422}],"compareEarnings":[{"period":"1week","weight":0.0325},{"period":"1month","weight":0.0505},{"period":"3month","weight":-0.0394},{"period":"6month","weight":-0.0562},{"period":"1year","weight":0.0055},{"period":"ytd","weight":-0.0194}],"compareStock":{"symbol":"HSI","name":"恒生指数"},"description":"宜明昂科生物医药技术（上海）股份有限公司是一家主要从事开发肿瘤免疫疗法的中国公司。该公司的主要业务包括开发用于系统利用先天性和适应性免疫的生物技术，以及开发下一代肿瘤免疫疗法，免疫疗法主要专注于适应性免疫系统。该公司的核心产品IMM01是创新靶向CD47的分子。该公司主要在中国国内和海外市场开展业务。","exchange":"SEHK","name":"宜明昂科-B","nameEN":"IMMUNEONCO-B"},"APP":{"userAgent":"Mozilla/5.0 AppleWebKit/537.36 (KHTML, like Gecko; compatible; ClaudeBot/1.0; +claudebot@anthropic.com)","isDev":false,"isTTM":false,"isLaohu8Offline":false,"tenantId":"TBCN","deviceId":"web-server-community-laohu8-v3","version":"4.44.1","shortVersion":"4.44.1","platform":"web","vendor":"web","appName":"laohu8","isIOS":false,"isAndroid":false,"isTiger":false,"isTHS":false,"isWeiXin":false,"isWeiXinMini":false,"isWeiBo":false,"isQQ":false,"isBaiduSwan":false,"isBaiduBox":false,"isDingTalk":false,"isToutiao":false,"isOnePlus":false,"isHuaWei":false,"isXiaomi":false,"isXiaomiWebView":false,"isOppo":false,"isVivo":false,"isSamsung":false,"isMobile":false},"pagemeta":{"title":"宜明昂科-B(01541)_个股概要_股票价格_最新资讯_行情走势_历史数据","description":"美港股上老虎。老虎社区提供宜明昂科-B(01541)今日价格,行情走势,历史数据,股票概要及实时的新闻资讯,近期大事等重要参考决策数据。","keywords":"宜明昂科-B,01541,宜明昂科-B股票,宜明昂科-B股票老虎,宜明昂科-B股票老虎国际,宜明昂科-B行情,宜明昂科-B股票行情,宜明昂科-B股价,宜明昂科-B股市,宜明昂科-B股票价格,宜明昂科-B股票交易,宜明昂科-B股票购买,宜明昂科-B股票实时行情,购买美股,购买港股,港股开户,美股开户,美股交易,港股交易,开通美港股账户,老虎国际行情","social":{"og_title":"宜明昂科-B(01541)_个股概要_股票价格_最新资讯_行情走势_历史数据","og_description":"美港股上老虎。老虎社区提供宜明昂科-B(01541)今日价格,行情走势,历史数据,股票概要及实时的新闻资讯,近期大事等重要参考决策数据。","og_image":"https://static.tigerbbs.com/a0b84b8debbbce3b4440f7fdd5eed2e7"}}}